Sugi Predict

Sugi Predict / Compounds / SCHEMBL22288342

SCHEMBL22288342

SCHEMBL22288342

COc1ccc(F)cc1-c1nc[nH]n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 3/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ FYN P06241 1/20 0.43
▸ JAK2 O60674 1/20 0.42
▸ JAK3 P52333 1/20 0.42
▸ CCNT1 O60563 9/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2302769 0.84 ALDH1A1 (0.50) MEN1NPC1USP2CYP1A2CYP3A4
SCHEMBL12127343 0.82 ALDH1A1 (0.50) LRRK2MEN1NPC1USP2RAB9A
SCHEMBL29685386 0.79 SYK (0.50) LRRK2USP2CYP1A2CYP3A4CYP2D6
SCHEMBL8940603 0.78 ERN1 (0.51) LRRK2MEN1NPC1USP2CYP1A2
SCHEMBL1528211 0.77 ALPL (0.41) —
SCHEMBL25751771 0.77 MAPT (0.50) MEN1CYP1A2CYP3A4MAPTCYP2C9
SCHEMBL9258717 0.76 ALDH1A1 (0.41) NPC1
SCHEMBL21994273 0.75 S1PR1 (0.42) LRRK2MEN1NPC1USP2CYP1A2
SCHEMBL23941153 0.73 CCNT1 (0.40) LRRK2JAK2JAK3CCNT1CDK9
SCHEMBL2666288 0.73 CYP1A2 (0.49) MEN1USP2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4538268-A1 PYRIDAZIN-3-CARBOXAMIDE COMPOUND AS TYK2 INHIBITOR Guangzhou Fermion Technology Co., Ltd. (CN) 2025-04-16 — — EP disclosed
CN-118978514-A Crystal form of pyridazine derivative free alkali, and preparation method and application thereof 上海翰森生物医药科技有限公司 2024-11-19 — — CN disclosed
CN-115667246-B Crystal form of pyridazine derivative free alkali, and preparation method and application thereof 上海翰森生物医药科技有限公司 2024-08-23 — — CN disclosed
CN-115448910-B Pyridazine derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2024-04-19 — — CN disclosed
US-20240101548-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) 2024-03-28 — — US disclosed
CN-117263918-A Pyridazine derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2023-12-22 — — CN disclosed
WO-2023236945-A1 PYRIDAZIN-3-CARBOXAMIDE COMPOUND AS TYK2 INHIBITOR 广州费米子科技有限责任公司 2023-12-14 — — WO disclosed
CN-117186074-A Pyridazine-3-carboxamide compounds as TYK2 inhibitors 广州费米子科技有限责任公司 2023-12-08 — — CN disclosed
EP-4257587-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2023-10-11 — — EP disclosed
CN-111757878-B Pyridazine derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2023-07-28 — — CN disclosed
CN-115667246-A Crystal form of pyridazine derivative free base and preparation method and application thereof 上海翰森生物医药科技有限公司 2023-01-31 — — CN disclosed
CN-115448910-A Pyridazine derivative inhibitor, and preparation method and application thereof 江苏豪森药业集团有限公司 2022-12-09 — — CN disclosed
CN-114901656-A Hydroximic acid ester compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2022-08-12 — — CN disclosed
WO-2022117016-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 深圳微芯生物科技股份有限公司 2022-06-09 — — WO disclosed
WO-2022117016-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 深圳微芯生物科技股份有限公司 2022-06-09 — — WO disclosed
WO-2022017494-A1 CRYSTAL FORM OF PYRIDAZINE DERIVATIVE FREE BASE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2022-01-27 — — WO disclosed
CN-113968846-A Salts and crystal forms of pyridazine derivatives, and preparation methods and applications of salts and crystal forms 上海翰森生物医药科技有限公司 2022-01-25 — — CN disclosed
CN-111757878-A Pyridazine derivative inhibitor, and preparation method and application thereof 江苏豪森药业集团有限公司 2020-10-09 — — CN disclosed
WO-2020156311-A1 PYRIDAZINE DERIVATIVE INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF 江苏豪森药业集团有限公司 2020-08-06 — — WO disclosed
WO-2020156311-A1 PYRIDAZINE DERIVATIVE INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF 江苏豪森药业集团有限公司 2020-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101548-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TYK2, WEE2, WEE1 LRRK2 623/4885MEN1 2163/4885NPC1 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.